Idose
Payments companies reported to CMS as associated with Idose. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Idose, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Idose
These are the largest totals companies reported as associated with Idose. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Oluwatosin Smith | Dallas, TX | Ophthalmology | $155,206.82 |
| Savak Teymoorian | Laguna Hills, CA | Ophthalmology | $101,502.37 |
| Wiley Chambers | Washington, DC | Ophthalmology | $57,600.00 |
| Inder Singh | Racine, WI | Ophthalmology | $46,472.47 |
| Christy Benson | Des Moines, IA | Ophthalmology | $42,128.18 |
| Jason Bacharach | Petaluma, CA | Glaucoma Specialist | $34,604.22 |
| John Micheletti | Houston, TX | Ophthalmology | $30,502.56 |
| Steven Sarkisian | Oklahoma City, OK | Glaucoma Specialist | $27,152.90 |
| Sahar Bedrood | Pasadena, CA | Retina Specialist | $26,857.40 |
| Iqbal Ahmed | Salt Lake City, UT | Ophthalmology | $25,812.50 |
Prescribed Idose?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.